deaths (OS)progression or deaths (PFS)RFS/DFS

la/mBC - HR-positive - 2nd line (L2) breast cancer - HR positive la/mBC - HR positive la/mBC - HR-positive - 2nd line (L2)

versus fulvestrant
buparlisib plus fulvestrant vs. fulvestrant 1 - certainty unassessablestatistically conclusive-30%-

la/mBC - HR positive - L2 - all population breast cancer - HR positive la/mBC - HR positive la/mBC - HR-positive - 2nd line (L2) la/mBC - HR positive - L2 - all population

versus fulvestrant
buparlisib plus fulvestrant vs. fulvestrant 1 certainty unassessable-12% certainty unassessablestatistically conclusive-20%-

la/mBC - HR positive - L2 - PIK3CA mutant breast cancer - HR positive la/mBC - HR positive la/mBC - HR-positive - 2nd line (L2) la/mBC - HR positive - L2 - PIK3CA mutant

versus fulvestrant
buparlisib plus fulvestrant vs. fulvestrant 1 - certainty unassessable-22%-